Epigenetic Changes to Inflammasome Found in Autoinflammatory Syndromes
Autoinflammatory syndromes manifest as periodic fevers in children, and are the result of monogenic, "gain in function" gene alterations affecting the inflammasome.
RheumNow Week in Review – 15 July 2016
Dr. Jack Cush reviews highlights from this week's rheumatology news on RheumNow.com.
Adalimumab Approved for Uveitis
Autoimmune ophthalmic disease is a frequent challenge to rheumatologists from both a diagnostic and therapeutic perspective. Approved therapies are limited and have only been infrequently or comfortably utilized by rheumatologists and autoimmune ophthalmologists.
GiACTA Study Shows Benefit of Adding Tocilizumab to Steroid Taper in Giant Cell Arteritis
The GiACTA study has published its top line results demonstrating the efficacy of adding tocilizumab (TCZ) to steroid-tapered therapy in patients with giant cell arteritis (GCA).
RheumNow Week in Review – 27 May 2016
Dr. Cush reviews highlights from this week on RheumNow.com.
RheumNow Week in Review - 19 May 2016
Dr. Jack Cush reviews this week's news and research highlights from RheumNow.com.
Biologic Prescribing and Patient Education
Biologics are big. Their popularity is reflected in their growing use since being introduced in 1998. Biologics have been used by more than 3 million patients worldwide.
KOLs Predict: What Will the Next Year Bring?
Executive Editor's Note: In honor of our 1st anniversary at RheumNow, we asked many leaders, teachers and researchers in rheumatology to think big and provide overviews of where we've been [yesterday'
Can Rituximab Change the Course of Interstitial Lung Disease?
Like other extraarticular manifestations, rheumatoid (RA) or connective tissue disease (CTD) related interstitial lung disease (ILD) is difficult to identify early and equally challenging to treat.
RheumNow Week in Review - 15 April 2016
Video recap of highlights from this week at RheumNow.com.
Biosimilar Reports - April 2016
Major advances in biosimilars have occurred in the last three months, beginning with the FDA Arthritis Advisory Committee voting 21-3 to approve Celltrion’s Inflectra (CT-P13) and ending with the recent approval of Inflectra (generically referred to as infliximab dyyb).
RheumNow Week in Review - 8 April 2016
Dr. Jack Cush reviews the rheumatology highlights from the news, media, and journals from this past week:
